Category: Entrepreneurship

“A Major Environmental Group” Will Fund Geoengineering Research

(p. A18) The Environmental Defense Fund will finance research into technologies that could artificially cool the planet, an idea that until recently was viewed as radical but is quickly gaining attention as global temperatures rise at alarming rates.

The group hopes to start issuing grants this fall, said Lisa Dilling, associate chief scientist at E.D.F., who is running the project. She said research would focus on estimating the likely effects in different parts of the world if governments were to deploy artificial cooling technologies.

. . .

The Environmental Defense Fund has previously expressed skepticism about techniques like these. But Dr. Dilling says the discussion about ways to cool the planet isn’t going away, regardless of opposition. “This is something that I don’t think we can just ignore,” she said.

The group will fund what is sometimes called solar radiation modification, or solar geoengineering, which involves reflecting more of the sun’s energy back into space. Possible techniques involve injecting aerosols into the stratosphere, or brightening clouds to make them more reflective.

. . .

That a major environmental group like the Environmental Defense Fund is investing in solar geoengineering research sends a powerful message, said Larry Birenbaum, a partner at the LAD Climate Fund, one of the groups funding the research. He said his group had been urging environmentalists for years to pay attention to solar geoengineering.

“We’re not going to convince everyone about the necessity for research,” said Mr. Birenbaum, a former senior vice president at Cisco Systems. “The climate community in general needs to be convinced, because this is on the fringe now, and it deserves not to be.”

For the full story see:

Christopher Flavelle. “Experiments to Artificially Cool the Earth Are Getting a Major Backer.” The New York Times (Tuesday, June 11, 2024): A18.

(Note: ellipses, and bracketed year, added.)

(Note: the online version of the story has the date June 10, 2024, and has the title “Environmental Group to Study Effects of Artificially Cooling Earth.”)

“America Is Where Everything Is Possible”

(p. 23) Remo Saraceni, a sculptor, toy inventor and technological fantasist best known for creating the Walking Piano that Tom Hanks and Robert Loggia danced on in a beloved scene of the hit 1988 movie “Big,” died on June 3 [2024] in Swarthmore, Pa. He was 89.

. . .

Remo Saraceni was born on Jan. 15, 1935, in Fossacesia, a city on the southern coast of Italy. His father, Giuseppe, worked with relatives to make shoes and other leather goods, and his mother, Filomena Carulli, managed the home.

Remo began inventing as a boy. His father got into trouble, he told The Chestnut Hill Local, when Remo turned a poster of Mussolini into a kite.

He took classes in electronics in Milan and worked as a radar specialist in the Italian military, but as a civilian he worked as a television repairman. He also started his own brand of large portable suitcase-like turntables. He came to the United States in 1964 for the World’s Fair and to seek a better livelihood — even though he spoke no English and had no American friends and no savings.

He again found work as a TV repairman and affixed a note to his bathroom mirror: “America is where everything is possible.”

For the full obituary see:

Alex Traub. “Remo Saraceni, 89; Invented Walking Piano in ‘Big’.” The New York Times, First Section (Sunday, June 16, 2024): 23.

(Note: ellipsis, and bracketed year, added.)

(Note: the online version of the obituary has the date June 14, 2024, and has the title “Remo Saraceni, 89, Dies; Inventor of the Walking Piano Seen in ‘Big’.”)

Europe’s Regulations Reduce Economic Dynamism

(p. A23) Growth and dynamism: In 1960 the E.U. 28 — the 27 countries currently in the European Union, plus Britain — accounted for 36.3 percent of global gross domestic product. By 2020 it had fallen to 22.4 percent. By the end of the century it is projected to fall to just under 10 percent. By contrast, the United States has maintained a roughly consistent share — around a quarter — of global G.D.P. since the Kennedy administration.

Think of any leading-edge industry — artificial intelligence, microchips, software, robotics, genomics — and ask yourself (with a few honorable exceptions), where’s the European Microsoft, Nvidia or OpenAI?

. . .

How much state protection, in social welfare and economic regulation, are Europe’s aging voters willing to forgo for the sake of creating a more dynamic economy for a dwindling number of young people?

For the full commentary, see:

Bret Stephens. “This D-Day, Europe Needs to Resolve to Get Its Act Together.” The New York Times (Wednesday, June 5, 2024): A23.

(Note: ellipsis added; bold font in original.)

(Note: the online version of the commentary has the date June 4, 2024, and has the same title as the print version.)

Alert Children Make “Staggering Discovery” That “Advances Science”

(p. D2) In the summer of 2022, two boys hiking with their father and a 9-year-old cousin in the North Dakota badlands came across some large bones poking out of a rock. They had no idea what to make of them.

The father took some photos and sent them to a paleontologist friend. Later, the relatives learned they’d made a staggering discovery: They’d stumbled upon a rare juvenile skeleton of a Tyrannosaurus rex.

. . .

The friend of the father who identified the fossil, Tyler Lyson, who is the museum’s curator of paleontology, said in a statement that the boys had made an “incredible dinosaur discovery that advances science and deepens our understanding of the natural world.”

. . .

In a video, the brothers, Jessin and Liam Fisher, 9 and 12, and their cousin, Kaiden Madsen, now 11, said that they were busy hiking and exploring when they first came across the bones and had no inkling they could be so special. “I didn’t have a clue,” Jessin says in the video. At first, he added, Dr. Lyson believed they belonged to a duck-billed dinosaur.

For the full story see:

Livia Albeck-Ripka. “Family Discovery: Stumbling Upon a Tyrannosaurus Rex In the Badlands of North Dakota.” The New York Times (Tuesday, June 11, 2024): D2.

(Note: ellipses added.)

(Note: the online version of the story was updated June 10, 2024, and has the title “Family Discovers Rare T. Rex Fossil in North Dakota.” Where the wording of the versions differs, the passages quoted above follow the online version.)

The study co-authored by Camarós, and mentioned above, is:

Tondini, Tatiana, Albert Isidro, and Edgard Camarós. “Case Report: Boundaries of Oncological and Traumatological Medical Care in Ancient Egypt: New Palaeopathological Insights from Two Human Skulls.” Frontiers in Medicine 11 (2024) DOI: 10.3389/fmed.2024.1371645.

On the antiquity of cancer, see also:

Haridy, Yara, Florian Witzmann, Patrick Asbach, Rainer R. Schoch, Nadia Fröbisch, and Bruce M. Rothschild. “Triassic Cancer—Osteosarcoma in a 240-Million-Year-Old Stem-Turtle.” JAMA Oncology 5, no. 3 (March 2019): 425-26.

Biden’s Tax and Regulation Plans Shift “Demonized” Silicon Valley Toward Trump

(p. B1) In 2021, David Sacks, a prominent venture capital investor and podcast host, said former President Donald J. Trump’s behavior around the Jan. 6 [2021] riot at the U.S. Capitol had disqualified him from being a future political candidate.

At a tech conference last week, Mr. Sacks said his view had changed.

“I have bigger disagreements with Biden than with Trump,” the investor said. Mr. Sacks said he and his podcast co-hosts were working on hosting a fund-raiser for Mr. Trump, which could include an interview for their “All In” show.  . . .

Such public support for Mr. Trump used to be taboo in Silicon Valley, which has long been seen as a liberal bastion. But frustration with Mr. Biden, Democrats and the state of the world has increasingly driven some of tech’s most prominent venture capitalists to the right.

. . .

(p. B5) Delian Asparouhov, an investor at Founders Fund, the investment firm founded by Mr. Thiel, recently marveled at how much the political winds had shifted. This month, Mr. Trump made a virtual appearance at a venture capital conference in Washington. There, he thanked attendees for “keeping your chin up” and said he looked forward to meeting them.

“Four years ago you had to issue an apology if you voted for him,” Mr. Asparouhov wrote on X.

Mr. Sacks, Mr. Palihapitiya and Founders Fund did not respond to a request for comment. Sequoia Capital declined to comment.

The comments and activity by the group of tech investors are particularly noticeable given Silicon Valley’s blue background.

. . .

The . . . “techlash” against Facebook and others caused some industry leaders to reassess their political views, a trend that continued through the social and political turmoil of the pandemic.

During that time, Democrats moved further to the left and demonized successful people who made a lot of money, further alienating some tech leaders, said Bradley Tusk, a venture capital investor and political strategist who supports Mr. Biden.

“If you keep telling someone over and over that they’re evil, they’re eventually not going to like that,” he said. “I see that in venture capital.”

That feeling has hardened under President Biden. Some investors said they were frustrated that his pick for chair of the Federal Trade Commission, Lina Khan, has aggressively moved to block acquisitions, one of the main ways venture capitalists make money. They said they were also unhappy that Mr. Biden’s pick for head of the Securities and Exchange Commission, Gary Gensler, had been hostile to cryptocurrency companies.

The start-up industry has also been in a downturn since 2022, with higher interest rates sending capital fleeing from risky bets and a dismal market for initial public offerings crimping opportunities for investors to cash in on their valuable investments.

Some also said they disliked Mr. Biden’s proposal in March [2024] to raise taxes, including a 25 percent “billionaire tax” on certain holdings that could include start-up stock, as well as a higher tax rate on profits from successful investments.

Mr. Sacks said at the tech conference last week that he thought such taxes could kill the start-up industry’s system of offering stock options to founders and employees. “It’s a good reason for Silicon Valley to think really hard about who it wants to vote for,” he said.

. . .

Mr. Andreessen, a founder of Andreessen Horowitz, a prominent Silicon Valley venture firm, said in a recent podcast that “there are real issues with the Biden administration.” Under Mr. Trump, he said, the S.E.C. and F.T.C. would be headed by “very different kinds of people.” But a Trump presidency would not necessarily be a “clean win” either, he added.

Last month, Mr. Sacks, Mr. Thiel, Elon Musk and other prominent investors attended an “anti-Biden” dinner in Hollywood, where attendees discussed fund-raising and ways to oppose Democrats, a person familiar with the situation said. The dinner was earlier reported by Puck.

For the full story see:

Erin Griffith. “Silicon Valley Notables Are Shifting to the Right.” The New York Times (Friday, May 24, 2024): B1 & B5.

(Note: ellipses, and bracketed years, added.)

(Note: the online version of the story has the date May 22, 2024, and has the title “Some of Silicon Valley’s Most Prominent Investors Are Turning Against Biden.”)

After Safe Drinking Water, Vaccines Were the Second “Most Successful Medical Interventions of the 20th Century”

(p. B11) Dr. Paul D. Parkman, whose research was instrumental in identifying the virus that causes rubella and developing a vaccine that has prevented an epidemic of the disease in the United States for more than 50 years, died on May 7 [2024] at his home in Auburn, N.Y., in the Finger Lakes region. He was 91.

. . .

In 1966, Dr. Parkman, Dr. Harry M. Meyer Jr. and their collaborators at the National Institutes of Health, including Maurice R. Hilleman, disclosed that they had perfected a vaccine to prevent rubella. Dr. Parkman and Dr. Meyer assigned their patents to the N.I.H. so that the vaccines could be manufactured, distributed and administered promptly.

“I never made a nickel from those patents because we wanted them to be freely available to everybody,” he said in an oral history interview for the N.I.H. in 2005.

President Lyndon B. Johnson thanked the researchers, noting that they were among the few who could “number themselves among those who directly and measurably advance human welfare, save precious lives, and bring new hope to the world.”

Still, after Dr. Parkman retired from the government in 1990, as director of the Food and Drug Administration’s Center for Biologics Evaluation and Research, he expressed concern about what he called the unfounded skepticism that persisted about the value of vaccines.

“With the exception of safe drinking water, vaccines have been the most successful medical interventions of the 20th century,” he wrote in 2002 in Food and Drug Administration Consumer, an agency journal.

For the full obituary see:

Sam Roberts. “Paul D. Parkman, 91, Researcher Whose Work Helped to Eliminate Rubella.” The New York Times (Friday, May 24, 2024): B11.

(Note: ellipses, and bracketed year, added.)

(Note: the online version of the obituary has the date May 21, 2024, and has the title “Dr. Paul Parkman, Who Helped to Eliminate Rubella, Dies at 91.”)

The 2002 article by Parkman mentioned above is:

Parkman, Paul D. “We Can’t Forget the Value of Vaccines.” Food and Drug Administration Consumer 36, no. 4 (July-Aug. 2002): 40.

Private-Sector Experimentation Versus Washington Inertia in the Fight for Longer Life

(p. A15) Amid today’s technological wizardry, it’s easy to forget that several decades have passed since a single innovation has dramatically raised the quality of life for millions of people. Summoning a car with one’s phone is nifty, but it pales in comparison with discovering penicillin or electrifying cities. Artificial intelligence is being heralded as the next big thing, but a cluster of scientists, technologists and investors are aiming higher. In the vernacular of Silicon Valley, where many of them are based, their goal is nothing less than disrupting death, and their story is at the center of “Immortality, Inc.” by science journalist Chip Walter.

. . .

That is the backdrop to Mr. Walter’s absorbing story, which he begins with a visit to Alcor, the Arizona-based organization that says it preserves corpses at minus 124 degrees Celsius “in an attempt to maintain brain viability after the heart stops.” (Current “patients” include baseball legend Ted Williams.) While this life-extending strategy, known as “cryonics,” is often ridiculed, the individuals profiled in “Immortality, Inc.” are high-status, highly regarded figures whose initiatives can’t be easily dismissed. What links them, writes Mr. Walter, is that “they are all troublemakers at heart.” They believe that the “conventional approaches” of most medical researchers and practitioners are, “at the very least, misguided.”

. . .

While “Immortality, Inc.” is focused on aging and the efforts to defy it, the book is also a gripping chronicle of private-sector experimentation and ingenuity in the face of inertia in Washington. “As recently as five years ago,” Mr. Walter writes, “the great pashas at [the National Institutes of Health] . . . looked upon aging research as largely crackpot.” He faults the Food and Drug Administration for refusing to classify aging as a disease. As a result, clinical trials—the foundation of medical research—can’t be conducted.

For the full review, see:

Matthew Rees. “BOOKSHELF; Birthdays Without End.” The Wall Street Journal (Monday, Jan. 27, 2020 [sic]): A15.

(Note: ellipses between paragraphs, added; ellipsis within paragraph, in original.)

(Note: the online version of the review has the date Jan. 26, 2020 [sic], and has the title “BOOKSHELF; ‘Immortality, Inc.’ Review: Birthdays Without End.”)

The book under review is:

Walter, Chip. Immortality, Inc.: Renegade Science, Silicon Valley Billions, and the Quest to Live Forever. Washington, D.C.: National Geographic, 2020.

Species Shifting Their Range Due to Climate Change May Have Enabled the “Playing Around With Resources” That Invented Farming

(p. D6) In the 1990s, archaeologists largely concluded that farming in the Fertile Crescent began in Jordan and Israel, a region known as the southern Levant. “The model was that everything started there, and then everything spread out from there, including maybe the people,” said Melinda A. Zeder, a senior research scientist at the Smithsonian National Museum of Natural History.

But in recent years, Dr. Zeder and other archaeologists have overturned that consensus. Their research suggests that people were inventing farming at several sites in the Fertile Crescent at roughly the same time. In the Zagros Mountains of Iran, for example, Dr. Zeder and her colleagues have found evidence of the gradual domestication of wild goats over many centuries around 10,000 years ago.

People may have been cultivating plants earlier than believed, too.

In the 1980s, Dani Nadel, then at Hebrew University, and his colleagues excavated a 23,000-year-old site on the shores of the Sea of Galilee known as Ohalo II. It consisted of half a dozen brush huts. Last year, Dr. Nadel co-authored a study showing that one of the huts contained 150,000 charred seeds and fruits, including many types, such as almonds, grapes and olives, that would later become crops. A stone blade found at Ohalo II seemed to have been used as a sickle to harvest cereals. A stone slab was used to grind the seeds. It seems clear the inhabitants were cultivating wild plants long before farming was thought to have begun.

“We got fixated on the very few things we just happened to see preserved in the archaeological record, and we got this false impression that this was an abrupt change,” Dr. Zeder said. “Now we really understand there was this long period where they’re playing around with resources.”

Many scientists have suggested that humans turned to agriculture under duress. Perhaps the climate of the Near East grew harsh, or perhaps the hunter-gatherer population outstripped the supply of wild foods.

But “playing around with resources” is not the sort of thing people do in times of desperation. Instead, Dr. Zeder argues, agriculture came about as climatic changes shifted the ranges of some wild species of plants and animals into the Near East.

Many different groups began experimenting with ways of producing extra food, which eventually enabled them to start a new way of life: settling down in more stable social groups.

For the full story see:

Carl Zimmer. “The First Farmers.” The New York Times (Tuesday, October 18, 2016 [sic]): D1 & D6.

(Note: the online version of the story has the date Oct. 17, 2016 [sic], and has the title “How the First Farmers Changed History.”)

The 2015 study co-authored by Dani Nadel and mentioned above is:

Snir, Ainit, Dani Nadel, Iris Groman-Yaroslavski, Yoel Melamed, Marcelo Sternberg, Ofer Bar-Yosef, and Ehud Weiss. “The Origin of Cultivation and Proto-Weeds, Long before Neolithic Farming.” PLOS ONE 10, no. 7 (July 22, 2015): e0131422.

Neuroscientists Confirm Folk Medicine Claims of Lavender’s Healing Powers

(p. D2) Lavender has purported healing powers for reducing stress and anxiety. But are these effects more than just folk medicine?

Yes, said Hideki Kashiwadani, a physiologist and neuroscientist at Kagoshima University in Japan — at least in mice.

. . .

In a study published Tuesday [Oct. 23, 2018 [sic]] in the journal Frontiers in Behavioral Neuroscience, he and his colleagues found that sniffing linalool, an alcohol component of lavender odor, was kind of like popping a Valium. It worked on the same parts of a mouse’s brain, but without all the dizzying side effects.

. . .

Their findings add to a growing body of research demonstrating anxiety-reducing qualities of lavender odors and suggest a new mechanism for how they work in the body.

For the full story see:

JoAnna Klein. “Purple Reigns: Folk Wisdom Hails Lavender’s Powers. Now Researchers Are Pinning Down Why.” The New York Times (Tuesday, October 30, 2018 [sic]): D2.

(Note: ellipses and bracketed date added.)

(Note: the online version of the story has the date Oct. 23, 2018 [sic], and has the title “Lavender’s Soothing Scent Could Be More Than Just Folk Medicine.” Where there is a small difference in wording between the versions, the passages quoted above follow the online version.)

The article co-authored by Kashiwadani and mentioned above is:

Harada, Hiroki, Hideki Kashiwadani, Yuichi Kanmura, and Tomoyuki Kuwaki. “Linalool Odor-Induced Anxiolytic Effects in Mice.” Frontiers in Behavioral Neuroscience 12 (Oct. 23, 2018).

Among Hoofed Mammals Outsiders Are More Likely to Innovate

(p. D2) Fair or not, goats have not earned a reputation for their problem-solving abilities.  . . .  But if you hide food in a strange cup and put a lid on it, a goat may find a way, a new study finds. And not just any goat, a team of researchers says. Animals that functioned like outsiders in their social group were best at tackling and solving a problem.

. . .

Mr. Caicoya and his colleagues looked at 13 species of hoofed mammals, with their study totaling 111 individuals living in zoos in Spain and Germany.

In a study published on Wednesday [April 12, 2023] in the Proceedings of the Royal Society B, Mr. Caicoya and his colleagues reported that around 38 percent of the animals avoided the cups entirely.

. . .

They found that animals that were outcasts or low in the pecking order had less fear of new objects, more willingness to explore them and a greater chance of getting the prize.

. . .

“The ones that are on the margins of the groups are the ones that are eating less and have more problems surviving in nature,” Mr. Caicoya said speculatively, “so those are the ones that normally take more risks to get food.”

Necessity, perhaps, is the mother of innovation.

For the full story see:

Veronique Greenwood. “Mammalian MacGyvers; Revenge of the Outsiders: Shunned Goats Solve Problems.” The New York Times (Tuesday, April 11, 2023 [sic]): D2.

(Note: ellipses, and bracketed date, added.)

(Note: the online version of the story has the date April 4, 2023 [sic], and has the title “Outsiders Solve Problems. Just Ask Goats.” The passages quoted above follow the wording in the lengthier online version.)

The study co-authored by Caicoya and mentioned above is:

Caicoya, Alvaro L., Alina Schaffer, Ruben Holland, Lorenzo von Fersen, Montserrat Colell, and Federica Amici. “Innovation across 13 Ungulate Species: Problem Solvers Are Less Integrated in the Social Group and Less Neophobic.” Proceedings of the Royal Society B: Biological Sciences 290, no. 1996 (2023): 20222384.

The “Rules of Desperation Oncology” Allow Oncologists to Throw Dying Patients a Hail Mary Immunotherapy Drug

(p. D1) Dr. Oliver Sartor has a provocative question for patients who are running out of time.

Most are dying of prostate cancer. They have tried every standard treatment, to no avail. New immunotherapy drugs, which can work miracles against a few types of cancer, are not known to work for this kind.

Still, Dr. Sartor, assistant dean for oncology at Tulane Medical School, asks a diplomatic version of this: Do you want to try an immunotherapy drug before you die?

The chance such a drug will help is vanishingly small — but not zero. “Under rules of desperation oncology, you engage in a different kind of oncology than the rational guideline thought,” Dr. Sartor said.

The promise of immunotherapy has drawn cancer specialists into a conundrum. When the drugs work, a cancer may seem to melt away overnight. But little is known about which patients might benefit, and from which drugs.

Some oncologists choose not to mention immunotherapy to dying patients, arguing that scientists first must gather rigorous evidence about the benefits and pitfalls, and that treating patients experimentally outside a clinical trial is perilous business.

But others, like Dr. Sartor, are offering the drugs to some terminal patients as a roll of the dice. If the patient is dying and there’s a remote chance the drug will help, then why not?

. . .

(p. D6) . . . there is Clark Gordin, 67, who lives in Ocean Springs, Miss. He had metastatic prostate cancer, “a bad deck of cards,” he said in an interview.

Dr. Sartor tried conventional treatments, but they didn’t work for Mr. Gordin. Finally, the doctor suggested immunotherapy.

Mr. Gordin’s insurer refused. But then the lab that had analyzed his tumor discovered it had made a mistake.

There was a chance Mr. Gordin might respond to immunotherapy, because he had a rare mutation. So his insurer agreed to pay.

Immediately after taking the drugs, Mr. Gordin’s PSA level — an indicator of the cancer’s presence — went down to nearly zero.

“Makes my heart nearly stop every time I think about it,” Dr. Sartor said. “Life sometimes hangs on a thin thread.”

For the full story see:

Gina Kolata. “A Life’s One Last Chance.” The New York Times (Tuesday, May 1, 2018 [sic]): D1 & D6.

(Note: ellipses added.)

(Note: the online version of the story has the date April 26, 2018 [sic], and has the title “‘Desperation Oncology’: When Patients Are Dying, Some Cancer Doctors Turn to Immunotherapy.”)